Apoptotic markers in cancer.

In cancer, apoptotic processes occur both spontaneously and induced by antitumor therapies. Qualitative and quantitative changes in cancer cell death along with proliferative alterations are essential determinants in the pathogenesis and progression of malignant disease and its responsiveness to therapy. Besides detecting apoptosis by invasive means in tumor tissue, apoptotic products can be quantified in the circulation. Although circulating apoptotic products usually lack organ and tumor specificity, they contribute in the assessment of disease extent or aggressiveness. The ease of drawing blood facilitates the serial measurement of circulating apoptotic markers to monitor antitumor treatment and predict early response to therapy. This review describes the features of apoptotic and necrotic cell death along with the role the balance between the rates of cell death and cell proliferation plays in the progression of malignancy. The intracellular pathways mediating apoptosis are next summarized. The focus then shifts to the apoptotic markers found in the circulation and their diagnostic, prognostic, predictive, and management utility in cancer.

[1]  John Savill,et al.  Corpse clearance defines the meaning of cell death , 2000, Nature.

[2]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[3]  B. Vojtesek,et al.  Release of cytokeratin‐18 and ‐19 fragments (TPS and CYFRA 21‐1) into the extracellular space during apoptosis , 2002, Journal of cellular biochemistry.

[4]  G. Kramer,et al.  Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.

[5]  C. Rodríguez,et al.  Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2002, Cancer.

[6]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[7]  S. Linder,et al.  Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.

[8]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[9]  Ronit Vogt Sionov,et al.  The cellular response to p53: the decision between life and death , 1999, Oncogene.

[10]  S. Ho,et al.  Monitoring Cytokeratin Fragment 19 (CYFRA 21-1) Serum Levels for Early Prediction of Recurrence of Adenocarcinoma and Squamous Cell Carcinoma in the Lung after Surgical Resection , 2002, Lung.

[11]  E. Slee,et al.  Serial killers: ordering caspase activation events in apoptosis , 1999, Cell Death and Differentiation.

[12]  P. Nicotera,et al.  Calcium and neuronal death. , 1998, Reviews of physiology, biochemistry and pharmacology.

[13]  H. Mellstedt,et al.  Increased serum levels of soluble Fas in progressive B‐CLL , 2001, European journal of haematology.

[14]  F. Laval,et al.  Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. , 1995, Cancer letters.

[15]  M. Ferdeghini,et al.  Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. , 2000, Cancer detection and prevention.

[16]  A. Desmoulière,et al.  Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. , 1997, The international journal of biochemistry & cell biology.

[17]  L. Pignataro,et al.  Soluble Fas (sFas) and soluble Fas ligand (sFas‐L) balance in laryngeal carcinoma before and after surgical treatment , 2003, Journal of surgical oncology.

[18]  Z. Darżynkiewicz,et al.  Assays of cell viability: discrimination of cells dying by apoptosis. , 1994, Methods in cell biology.

[19]  S. Ugurel,et al.  Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  B. Osborne,et al.  Cell death in the third millennium , 2000, Cell Death and Differentiation.

[21]  D. Ucker Death and dying in the immune system. , 1997, Advances in pharmacology.

[22]  Y. Chung,et al.  Clinical significance of serum CYFRA 21-1 in gastric cancer. , 1996, British Journal of Cancer.

[23]  R. Govindan,et al.  Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  L. Zhang,et al.  Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.

[25]  J F Kerr,et al.  Shrinkage necrosis: A distinct mode of cellular death , 1971, The Journal of pathology.

[26]  T. Majima,et al.  Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. , 2001, Oncology reports.

[27]  U. Pastorino,et al.  Detecting lung cancer in plasma with the use of multiple genetic markers , 2004, International journal of cancer.

[28]  R. Stahel,et al.  Circulating DNA: a new diagnostic gold mine? , 2002, Cancer treatment reviews.

[29]  J. Pujol,et al.  Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. , 1996, American journal of respiratory and critical care medicine.

[30]  M. Untch,et al.  Nucleosomes in serum of patients with benign and malignant diseases , 2001, International journal of cancer.

[31]  B. Persson,et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.

[32]  A. Cossarizza,et al.  Control of apoptosis by the cellular ATP level , 1996, FEBS letters.

[33]  S. Leung,et al.  Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. , 1999, Cancer research.

[34]  P. Nicotera,et al.  Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.

[35]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.

[36]  Qi-Lian Liang,et al.  [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.

[37]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[38]  Jiazhen Le,et al.  Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma , 2003, The Journal of Laryngology & Otology.

[39]  N. Niitsu,et al.  A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin’s lymphoma , 1999, Leukemia.

[40]  Roger Y. Tsien,et al.  Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis , 2000, Nature Cell Biology.

[41]  M. Toi,et al.  Plasma nucleosome levels in node-negative breast cancer patients , 1999, Breast cancer.

[42]  H. Kuwano,et al.  Circulating soluble Fas ligand in patients with gastric carcinoma , 2000, Cancer.

[43]  S. Yang,et al.  Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. , 2002, Anticancer research.

[44]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[45]  M. Toi,et al.  Circulating soluble Fas concentration in breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Y. Kanda,et al.  Lack of Correlation Between Clinical Characteristics and Serum Soluble Fas Ligand Levels in Patients with Multiple Myeloma , 2001, Leukemia & lymphoma.

[47]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[48]  M. Takemura,et al.  Serum‐soluble Fas level determines clinical symptoms and outcome of patients with aggressive non‐Hodgkin's lymphoma , 2000, American journal of hematology.

[49]  M. Stroun,et al.  Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease , 2001, Leukemia.

[50]  H Dienemann,et al.  CYFRA 21‐1: A new marker in lung cancer , 1993, Cancer.

[51]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[52]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[53]  B. Zhivotovsky,et al.  Apoptosis in human disease: a new skin for the old ceremony? , 1999, Biochemical and biophysical research communications.

[54]  L. Ceriani,et al.  Serum Cytokeratin Fragment 21.1 (CYFRA 21.1) as Tumour Marker for Breast Cancer: Comparison with Carbohydrate Antigen 15.3 (CA 15.3) and Carcinoembryonic Antigen (CEA) , 2002, Clinical chemistry and laboratory medicine.

[55]  A. Heinecke,et al.  CYFRA 21-1 serum analysis in patients with esophageal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  M. Monden,et al.  [Tumor markers for colorectal cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.

[57]  D. Bredesen,et al.  An alternative, nonapoptotic form of programmed cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Kaufmann,et al.  Methods utilized in the study of apoptosis. , 1997, Advances in pharmacology.

[59]  S. Leung,et al.  Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.

[60]  K. Nasu,et al.  Serum levels of cytokeratin 19 fragments in cervical cancer. , 1996, Gynecologic and obstetric investigation.

[61]  J. Werner,et al.  Follow-Up with Serum Cyfra 21-1 in Patients with Squamous Cell Carcinomas of the Head and Neck , 2002, Oncology.

[62]  H. Dienemann,et al.  Comparison of Cytokeratin Fragment 19 (CYFRA 21-1), Tissue Polypeptide Antigen (TPA) and Tissue Polypeptide Specific Antigen (TPS) as Tumour Markers in Lung Cancer , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[63]  B. Beghé,et al.  Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. , 1995, Quarterly Journal of Nuclear Medicine.

[64]  E. Lane,et al.  Lung Cancer-Associated Keratin 19 Fragments: Development and Biochemical Characterisation of the New Serum Assay Enzymun-Test® Cyfra 21–1 , 1994, The International journal of biological markers.

[65]  Dean P. Jones,et al.  Apoptosis: Cell death defined by caspase activation , 1999, Cell Death and Differentiation.

[66]  Z. Darżynkiewicz,et al.  Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). , 1997, Cytometry.

[67]  P. Stieber,et al.  Apoptosis in serum of patients with solid tumours. , 1999, Anticancer research.

[68]  L. Mariani,et al.  Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.

[69]  A. Wyllie,et al.  Apoptosis. The role of the endonuclease. , 1990, The American journal of pathology.

[70]  Y Chiba,et al.  Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  X. M. Sun,et al.  Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. , 1992, The Biochemical journal.

[72]  G. Majno,et al.  Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.

[73]  C. Steinman,et al.  Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome‐like structure and clearance , 1992, Clinical and experimental immunology.

[74]  A. Maebo,et al.  [Plasma DNA level as a tumor marker in primary lung cancer]. , 1990, Nihon Kyobu Shikkan Gakkai zasshi.

[75]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[76]  L. Hefler,et al.  Serum Soluble Fas Levels in Ovarian Cancer , 2000, Obstetrics and gynecology.

[77]  V. Fadok,et al.  Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. , 1992, Journal of immunology.

[78]  Tomomi Sato,et al.  Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level , 1998, Journal of Gastroenterology.

[79]  S Niho,et al.  [Tumor markers in lung cancer]. , 2001, Gan to kagaku ryoho. Cancer & chemotherapy.

[80]  N. Nonomura,et al.  Soluble Fas in serum from patients with renal cell carcinoma. , 2000, Urology.

[81]  B. Stewart Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. , 1994, Journal of the National Cancer Institute.

[82]  Jia-qing Li,et al.  CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. , 2002, International journal of oncology.

[83]  Luciana Dini,et al.  Cell death: apoptosis versus necrosis (review). , 2002, International journal of oncology.

[84]  S. Leung,et al.  Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. , 2000, Cancer research.

[85]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[86]  H. Dienemann,et al.  Comparison of Cyfra 21–1, Tpa and Tps in Lung Cancer, Urinary Bladder Cancer and Benign Diseases , 1994, The International journal of biological markers.

[87]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[88]  M. Páez de la Cadena,et al.  Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. , 2003, Oncology reports.

[89]  G. Prindull Apoptosis in the embryo and tumorigenesis. , 1995, European journal of cancer.

[90]  J. Pujol,et al.  Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. , 1998, Cancer detection and prevention.

[91]  M. Leist,et al.  In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells. , 2001, Biochemical and biophysical research communications.

[92]  T. Takano,et al.  Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[94]  J. Kerr,et al.  Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. , 1992, International journal of radiation biology.

[95]  P. Krammer CD95(APO-1/Fas)-mediated apoptosis: live and let die. , 1999, Advances in immunology.

[96]  A. Takise,et al.  CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. , 1997, Oncology.

[97]  A. Dueñas-González,et al.  Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients , 2003, International journal of cancer.

[98]  P. Clarke,et al.  Nineteenth century research on naturally occurring cell death and related phenomena , 1996, Anatomy and Embryology.

[99]  A. Glücksmann CELL DEATHS IN NORMAL VERTEBRATE ONTOGENY , 1951 .

[100]  H. Mulcahy,et al.  Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: Time for large‐scale clinical studies? , 2003, International journal of cancer.

[101]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[102]  Michael Thomas,et al.  Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. , 2002, Lung cancer.

[103]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[104]  D. Nicholson,et al.  Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.

[105]  J. Weinberg,et al.  Apoptosis: definition, mechanisms, and relevance to disease. , 1999, The American journal of medicine.

[106]  P. Schär,et al.  Spontaneous DNA Damage, Genome Instability, and Cancer—When DNA Replication Escapes Control , 2001, Cell.

[107]  M. Toi,et al.  Clinical significance of plasma nucleosome levels in cancer patients. , 2001, International journal of oncology.

[108]  K. Feldmann,et al.  Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[109]  K. Braithwaite,et al.  Multi-step evolution of lung cancer. , 1999, Seminars in cancer biology.

[110]  Lakshmi Goyal Cell Death Inhibition Keeping Caspases in Check , 2001, Cell.

[111]  M. Andreeff,et al.  Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. , 1997, Leukemia & lymphoma.

[112]  V. Lipkin,et al.  Soluble Fas Antigen in the Serum of Patients with Colon Cancer , 2001, Bulletin of Experimental Biology and Medicine.

[113]  J L Pujol,et al.  Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. , 2001, Lung cancer.

[114]  P. Nicotera,et al.  Execution of Apoptosis: Converging or Diverging Pathways? , 1999, Biological chemistry.

[115]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[116]  T. Mak,et al.  Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death , 2001, Nature.

[117]  P. Krammer,et al.  Molecular Mechanisms of Death‐Receptor‐Mediated Apoptosis , 2001, Chembiochem : a European journal of chemical biology.

[118]  Mariano Provencio,et al.  Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[120]  B. McManus,et al.  Apoptosis: molecular aspects of cell death and disease. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[121]  H. Nakahama,et al.  CYFRA 21‐1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients , 1998, Respirology.

[122]  John Calvin Reed,et al.  Endogenous Inhibitors of Caspases , 1999, Journal of Clinical Immunology.

[123]  S. Sheen-Chen,et al.  Circulating Soluble Fas in Patients with Breast Cancer , 2003, World Journal of Surgery.

[124]  B. Zhivotovsky,et al.  ‘Centennial’ Nobel Conference on apoptosis and human disease , 2002, Cell Death and Differentiation.

[125]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[126]  John Calvin Reed Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. , 1997, Advances in pharmacology.

[127]  R. Weiss,et al.  Urine detection of survivin and diagnosis of bladder cancer. , 2001, JAMA.

[128]  S. Sun,et al.  Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. , 2000, American journal of clinical oncology.

[129]  Y. Tomita,et al.  Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients , 1999, British Journal of Cancer.

[130]  K. Sasajima,et al.  Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus , 1999, Medical oncology.

[131]  Marcel Leist,et al.  Four deaths and a funeral: from caspases to alternative mechanisms , 2001, Nature Reviews Molecular Cell Biology.

[132]  R. Molina,et al.  Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[133]  N. Viñolas,et al.  Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis , 2003, Tumor Biology.

[134]  Y. Mizutani,et al.  Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. , 2002, Cancer biotherapy & radiopharmaceuticals.

[135]  H. D. de Bruijn,et al.  Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. , 2002, International journal of radiation oncology, biology, physics.

[136]  U. Pastorino,et al.  Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer , 2003 .

[137]  C. Hess,et al.  Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. , 2002, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[138]  R. Neumann,et al.  Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. , 2003, Oncology reports.

[139]  C. Kao,et al.  Comparison of Cyfra 21–1 and Squamous Cell Carcinoma Antigen in Detecting Nasopharyngeal Carcinoma , 2001, Annals of Otology, Rhinology and Laryngology.

[140]  S. Leung,et al.  Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. , 2003, Cancer research.

[141]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[142]  A. Hart,et al.  Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. , 1994, Gynecologic oncology.

[143]  A. Hart,et al.  Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. , 1999, Lung cancer.

[144]  R. Hodes,et al.  What Does Cell Death Have To Do with Aging? , 1997, Journal of the American Geriatrics Society.

[145]  P. Stieber,et al.  Circulating Nucleosomes in Serum , 2001, Annals of the New York Academy of Sciences.

[146]  P. Lamy,et al.  Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. , 2003, Lung cancer.

[147]  M. Jäättelä,et al.  Escaping cell death: survival proteins in cancer. , 1999, Experimental cell research.

[148]  M. Untch,et al.  Nucleosomes in Serum as a Marker for Cell Death , 2001, Clinical chemistry and laboratory medicine.

[149]  P Stieber,et al.  Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. , 1994, Anticancer research.

[150]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[151]  P. Nicotera,et al.  Intracellular ATP, a switch in the decision between apoptosis and necrosis. , 1998, Toxicology letters.

[152]  M. Hengartner Apoptosis Corralling the Corpses , 2001, Cell.

[153]  D. Ferrigno,et al.  Lung tumor markers of cytokeratin origin: an overview. , 2001, Lung cancer.

[154]  John Calvin Reed Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[156]  E. Altieri,et al.  Cyfra 21-1 marker in carcinoma of the cervix. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[157]  P. Johnson,et al.  Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[158]  J. Hickman,et al.  Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. , 1993, The EMBO journal.

[159]  M. Lutter,et al.  Biochemical pathways of caspase activation during apoptosis. , 1999, Annual review of cell and developmental biology.

[160]  H. Dienemann,et al.  Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. , 2003, Anticancer research.

[161]  P. Williamson,et al.  Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes , 1995, The Journal of experimental medicine.

[162]  T. Uenishi,et al.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer , 2003, British Journal of Cancer.

[163]  Y. Mizutani,et al.  Significance of serum soluble fas ligand in patients with bladder carcinoma , 2001, Cancer.

[164]  Rachel L. Allen,et al.  Defying death after DNA damage , 2000, Nature.

[165]  D. Khayat,et al.  Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma , 2000, Melanoma research.

[166]  J. Daurès,et al.  Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.

[167]  V. Vasioukhin,et al.  The Origin and Mechanism of Circulating DNA , 2000, Annals of the New York Academy of Sciences.

[168]  Apoptosis regulators and their role in tumorigenesis. , 2001 .

[169]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[170]  L. Ceriani,et al.  Immunoassay of Neuron-Specific Enolase (Nse) and Serum Fragments of Cytokeratin 19 (Cyfra 21.1) as Tumor Markers in Small Cell Lung Cancer: Clinical Evaluation and Biological Hypothesis , 1997, The International journal of biological markers.

[171]  S. Umansky,et al.  Circulating Nucleic Acids and Apoptosis , 2001, Annals of the New York Academy of Sciences.

[172]  T. Cotter,et al.  Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. , 1990, Anticancer research.

[173]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.